MA34146B1 - Formulations oralles et sels lipophiles de methylnaltrexone - Google Patents

Formulations oralles et sels lipophiles de methylnaltrexone

Info

Publication number
MA34146B1
MA34146B1 MA35290A MA35290A MA34146B1 MA 34146 B1 MA34146 B1 MA 34146B1 MA 35290 A MA35290 A MA 35290A MA 35290 A MA35290 A MA 35290A MA 34146 B1 MA34146 B1 MA 34146B1
Authority
MA
Morocco
Prior art keywords
methylnaltrexone
oral formulations
lipophilic salts
lipophilic
salts
Prior art date
Application number
MA35290A
Other languages
English (en)
Inventor
Syed M Shah
Christopher Richard Diorio
Eric C Ehrnsperger
Xu Meng
Shareffi Kadum A Al
Jonathan Marc Cohen
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34146(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MA34146B1 publication Critical patent/MA34146B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Abstract

La présente invention a pour objet des compositions comprenant de la méthylnaltrexone ou son sel, et leurs compositions et leurs formulations, pour une administration orale.
MA35290A 2010-03-11 2011-03-10 Formulations oralles et sels lipophiles de methylnaltrexone MA34146B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
PCT/US2011/027913 WO2011112816A1 (fr) 2010-03-11 2011-03-10 Formulations orales et sels lipophiles de méthylnaltrexone

Publications (1)

Publication Number Publication Date
MA34146B1 true MA34146B1 (fr) 2013-04-03

Family

ID=44148539

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35290A MA34146B1 (fr) 2010-03-11 2011-03-10 Formulations oralles et sels lipophiles de methylnaltrexone

Country Status (32)

Country Link
US (8) US8524276B2 (fr)
EP (2) EP2371357B1 (fr)
JP (4) JP6143409B2 (fr)
KR (2) KR101913102B1 (fr)
CN (2) CN107308125B (fr)
AR (1) AR080491A1 (fr)
AU (1) AU2011224275B2 (fr)
BR (1) BR112012022873B1 (fr)
CA (1) CA2789798C (fr)
CL (1) CL2012002192A1 (fr)
CO (1) CO6630134A2 (fr)
CR (1) CR20120476A (fr)
EA (1) EA029096B1 (fr)
EC (1) ECSP12012208A (fr)
ES (1) ES2623926T3 (fr)
GE (1) GEP201606550B (fr)
GT (1) GT201200247A (fr)
HK (1) HK1245673A1 (fr)
HU (1) HUE033133T2 (fr)
IL (1) IL221452A (fr)
MA (1) MA34146B1 (fr)
MX (2) MX349145B (fr)
MY (1) MY160727A (fr)
NZ (3) NZ703564A (fr)
PE (1) PE20130063A1 (fr)
PL (2) PL2371357T3 (fr)
SG (3) SG10201606618PA (fr)
TN (1) TN2012000392A1 (fr)
TW (2) TWI605814B (fr)
UA (2) UA123856C2 (fr)
WO (1) WO2011112816A1 (fr)
ZA (1) ZA201808498B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
EP2164960A2 (fr) 2007-05-25 2010-03-24 North Carolina State University Plate-forme pour l'apport, ciblé sur des cellules, de nanoparticules virales
MX349145B (es) 2010-03-11 2017-07-14 Wyeth Llc * Formulaciones orales y sales lipofilicas de metilnaltrexona.
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
CN104254332A (zh) * 2011-12-19 2014-12-31 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
WO2015191686A1 (fr) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Procédés d'administration de méthylnaltrexone
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (fr) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Aerosol sublingual de naloxone
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3718404A1 (fr) 2014-10-17 2020-10-07 Salix Pharmaceuticals, Inc. Utilisation de méthylnaltrexone pour atténuer la progression de tumeurs
JP2022531685A (ja) * 2019-05-07 2022-07-08 バウシュ ヘルス アイルランド リミテッド メチルナルトレキソンの液体経口投与製剤
WO2020245214A1 (fr) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Utilisation de méthylnaltrexone et de rifaximine pour le traitement d'une perméabilité intestinale accrue ou de troubles associés
WO2021224138A1 (fr) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Procédés de réduction du risque de mortalité chez des sujets souffrant d'une maladie ou d'une affection sous-jacente par administration de méthylnaltrexone
WO2023031955A1 (fr) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Compositions pharmaceutiques orales de méthylnaltrexone et sel associé

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (fr) 1986-03-14 1992-03-10 Edward David Weil Additif pour les plastiques retardant la propagation de la flamme de type diphosphonate, thermiquement stable
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (fr) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Appariement d'ions de medicaments pour ameliorer l'efficacite et l'administration
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998035679A1 (fr) 1997-02-14 1998-08-20 Gödecke Aktiengesellschaft Stabilisation d'hydrochlorure de naloxone
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP0913152B1 (fr) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Composition stabilisée d'une combinaison de substances actives comprenant de la naloxone et un opioide analgésique
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
ATE493130T1 (de) * 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030022909A1 (en) 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
EP2939696B1 (fr) 2001-10-18 2016-03-09 Nektar Therapeutics Conjugués de polymère d'antagonistes d'opioïdes
EP1451174B1 (fr) * 2001-11-29 2010-08-18 Schering Corporation Procede de preparation de compositions presentant une quantite augmentee de sels pharmaceutiquement actifs de rotameres
WO2003077867A2 (fr) 2002-03-14 2003-09-25 Euro-Celtique, S.A. Compositions a base de chlorhydrate de naltrexone
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
US20050004155A1 (en) 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
CN104383542B (zh) 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
CA2532302C (fr) * 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Procede de preparation de compositions a liberation controlee
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
KR20060111581A (ko) 2003-12-19 2006-10-27 쉐링 코포레이션 약제학적 조성물
JP2007517015A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬物、ポロキサマーおよび安定化ポリマーの安定化された医薬用固体組成物
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
WO2006039705A2 (fr) 2004-09-30 2006-04-13 Becton, Dickinson And Company Procede permettant de reduire ou d'eliminer des residus dans un contenant en verre et contenant en verre ainsi obtenu
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (fr) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation
US8091568B2 (en) * 2006-08-16 2012-01-10 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
CA2665726C (fr) * 2006-10-11 2016-04-19 Alpharma, Inc. Compositions pharmaceutiques
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
AU2008233133B2 (en) * 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
EA201001643A1 (ru) * 2008-05-07 2011-06-30 Нектар Терапеутикс Пероральное введение периферически действующих опиоидных антагонистов
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
MX349145B (es) 2010-03-11 2017-07-14 Wyeth Llc * Formulaciones orales y sales lipofilicas de metilnaltrexona.
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
HK1245673A1 (zh) 2018-08-31
PE20130063A1 (es) 2013-02-11
EP2371357A1 (fr) 2011-10-05
US10307417B2 (en) 2019-06-04
TW201622724A (zh) 2016-07-01
MX2012009125A (es) 2012-09-07
AU2011224275A1 (en) 2012-08-23
PL2371357T3 (pl) 2017-09-29
CN107308125B (zh) 2021-07-16
GEP201606550B (en) 2016-10-10
US20190117645A1 (en) 2019-04-25
CN102918039A (zh) 2013-02-06
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
IL221452A (en) 2017-07-31
US20140249171A1 (en) 2014-09-04
US10507206B2 (en) 2019-12-17
JP2019034958A (ja) 2019-03-07
CL2012002192A1 (es) 2012-09-28
US10376505B2 (en) 2019-08-13
SG10201606618PA (en) 2016-09-29
TW201141479A (en) 2011-12-01
MY160727A (en) 2017-03-15
US20190314365A1 (en) 2019-10-17
CA2789798C (fr) 2020-09-22
US20200121673A1 (en) 2020-04-23
CN107308125A (zh) 2017-11-03
UA111717C2 (uk) 2016-06-10
EA029096B1 (ru) 2018-02-28
ZA201808498B (en) 2019-08-28
NZ703564A (en) 2016-08-26
NZ601595A (en) 2015-01-30
CR20120476A (es) 2012-11-30
JP6429955B2 (ja) 2018-11-28
JP2011190259A (ja) 2011-09-29
BR112012022873A2 (pt) 2016-08-30
SG183133A1 (en) 2012-09-27
GT201200247A (es) 2013-09-11
JP2016029054A (ja) 2016-03-03
ES2623926T3 (es) 2017-07-12
US8524276B2 (en) 2013-09-03
WO2011112816A1 (fr) 2011-09-15
US20130330407A1 (en) 2013-12-12
TWI605814B (zh) 2017-11-21
TWI589293B (zh) 2017-07-01
CO6630134A2 (es) 2013-03-01
HUE033133T2 (en) 2017-11-28
UA123856C2 (uk) 2021-06-16
US20160206612A1 (en) 2016-07-21
ECSP12012208A (es) 2015-03-31
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (fr) 2011-09-15
CN102918039B (zh) 2017-06-09
NZ702826A (en) 2016-08-26
AR080491A1 (es) 2012-04-11
KR101913102B1 (ko) 2018-10-31
EP2371357B1 (fr) 2017-02-01
MX349145B (es) 2017-07-14
EP3178472B1 (fr) 2021-10-27
BR112012022873B1 (pt) 2021-09-14
EP3178472A1 (fr) 2017-06-14
MX368805B (es) 2019-10-17
JP6647368B2 (ja) 2020-02-14
KR101982482B1 (ko) 2019-05-27
JP2017206553A (ja) 2017-11-24
SG10201501821RA (en) 2015-05-28
US9314461B2 (en) 2016-04-19
TN2012000392A1 (en) 2014-01-30
IL221452A0 (en) 2012-10-31
US20120070495A1 (en) 2012-03-22
EA201270741A1 (ru) 2013-02-28
US20190117646A1 (en) 2019-04-25
US8956651B2 (en) 2015-02-17
KR20130010900A (ko) 2013-01-29
JP6143409B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
MA34146B1 (fr) Formulations oralles et sels lipophiles de methylnaltrexone
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA201170227A1 (ru) Имидазолкарбоксамиды
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BRPI0909738A2 (pt) composições farmacêuticas aquosas contendo complexos de boratopoliol
MX346936B (es) Metodo, composiciones y empaque para limpieza del intestino.
ATE530170T1 (de) Paliperidonformulierung mit verzögerter freisetzung
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201170483A1 (ru) Твердая фармацевтическая композиция
EA201492029A1 (ru) N-этил-4-гидроксил-1-метил-5-(метил(2,3,4,5,6-пентагидроксигексил)амино)-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
ITTO20110273A1 (it) Composizione di base per composizione cosmetica oppure farmaceutica.
MA34709B1 (fr) Compositions pharmaceutiques
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
WO2010077669A3 (fr) Formulation de palonosétron
TR201007926A1 (tr) Prasugrel tablet formülasyonları.